GlassScriptPhysician profile
Apurva Bansal
NPI 1962884429
$14,500.01
in general payments reported to CMS, 2019-2025
28 companies · $11K in 2025
The $11K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.03 · 2021: $214 · 2022: $853 · 2023: $1,069 · 2024: $1,009 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,534 · Food and Beverage: $3,561 · Travel and Lodging: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,534.00 |
| Food and Beverage | $3,561.21 |
| Travel and Lodging | $1,315.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,138.34 | 2023-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $1,670.01 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $395.52 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $347.52 | 2021-2025 | Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.76 | 2020-2025 | Ofev |
| Grifols USA, LLC | $270.06 | 2021-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $262.63 | 2021-2024 | Yupelri |
| Insmed, INC. | $262.24 | 2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $110.24 | 2021-2024 | |
| Viatris Specialty LLC | $96.47 | 2025 | Yupelri |
| Gilead Sciences, INC. | $88.71 | 2022-2023 | |
| Genzyme Corporation | $88.20 | 2023-2025 | |
| Amgen INC. | $74.00 | 2024-2025 | Tezspire |
| Electromed, INC. | $52.23 | 2024-2025 | Smartvest |
| Verona Pharma, INC. | $39.43 | 2025 | Ohtuvayre |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $39.32 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Paratek Pharmaceuticals, INC. | $36.29 | 2022 | |
| United Therapeutics Corporation | $34.76 | 2021-2022 | |
| Fisher & Paykel Healthcare INC | $25.85 | 2023 | Fisher & Paykel Healthcare |
| Ambu INC. | $24.73 | 2023 | |
| Abbvie INC. | $23.72 | 2023 | Teflaro |
| Alexion Pharmaceuticals, INC. | $21.67 | 2023 | Soliris |
| Merck Sharp & Dohme LLC | $21.17 | 2023 | |
| Mallinckrodt Hospital Products INC. | $18.54 | 2023 | Acthar |
| Lilly USA, LLC | $18.04 | 2025 | Mounjaro |
| Philips North America LLC | $16.93 | 2022 | |
| Genentech USA, INC. | $15.74 | 2022 | |
| Advanced Respiratory, INC | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Apurva Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.